Hydrophilic coatings including a base coat layer and a top coat layer wherein at least one of the base coat and top coat compositions that form the hydrophilic coatings comprises a diacrylate compound have a number average molecular weight less than 1000.

A lubricating coating including at least one polymer A, a cross-linker and at least one lubricating agent, and wherein a portion of the at least two reactive groups of the cross-linker are covalently linked to the polymer A to form a three-dimensional network in which the lubricant is incorporated, and wherein at the same time another portion of the reactive groups of the cross-linker are covalently linked to the surface of the device or to the optional adhesion layer on the surface of the device.

Embodiments of the present disclosure provide for lubricious structures (also referred to simply as “structure”), methods of making lubricious structures, methods of using lubricious structures, and the like.

A first alternative to a composition for preventing or retarding degradation of a functional coating on a medical device comprising an antioxidant selected from gallic acid or a derivative thereof. A second alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes carboxymethyl cellulose or a derivative or salt thereof. The use of the compositions for preventing or retarding degradation of a functional coating on a medical device from reactive species generated during exposure of radiation, and a wetting agent comprising the compositions, are also provided. The wetting agent prevents or retards the hydrolytic degradation of the coating during the intended shelf-life of the wetted coated product.

A first alternative to a composition for preventing or retarding degradation of a functional coating on a medical device comprising an antioxidant selected from gallic acid or a derivative thereof. A second alternative to a composition for preventing or retarding degradation of a functional coating on a medical device includes carboxymethyl cellulose or a derivative or salt thereof. The use of the compositions for preventing or retarding degradation of a functional coating on a medical device from reactive species generated during exposure of radiation, and a wetting agent comprising the compositions, are also provided. The wetting agent prevents or retards the hydrolytic degradation of the coating during the intended shelf-life of the wetted coated product.

Durable, anti-fouling, crosslinked zwitterionic coatings that are grafted to the surface of a substrate through covalent bonding are disclosed. When exposed to a light source, zwitterionic monomers react with a crosslinker and with activated radicals at the surface of the substrate, simultaneously forming the crosslinked zwitterionic coating and anchoring it to the surface of the substrate. Photomasking techniques can be used to micropattern the zwitterionic coatings. The zwitterionic coatings can be applied to a variety of substrates, including medical devices and systems.

An example medical device includes a vascular device, such as a catheter, and an anti-thrombogenic coating on a surface of the vascular device, such as a surface likely to contact blood. The anti-thrombogenic coating includes one or more peptides configured to interact with fibrinogen in the blood, such as a first type of peptides configured to bind to fibrinogen a second type of peptides configured to inhibit conversion of fibrinogen to fibrin. The anti-thrombogenic coating also includes a polymer, such as a hydrocolloid polymer, a tunable polyethylene glycol (PEG), or other controlled release polymer configured to control release of the one or more peptides and maintain a concentration of the peptides at the surface of the anti-thrombogenic coating above a minimum inhibitory concentration, thereby inhibiting thrombin formation on the intravascular medical device.

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Embodiments of the present invention provide a method of treating a stricture in a nonvascular body lumen such as urethral strictures, benign prostatic hyperplasia (BPH) strictures, ureteral strictures, esophageal strictures, sinus strictures, and biliary tract strictures. Embodiments of the present invention provide a method for treating at least one of benign prostatic hyperplasia (BPH), prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). The method can include delivering, for example, via drug coated balloon catheters, anti-inflammatory and anti-proliferative drugs (e.g., rapamycin, paclitaxel, and their analogues) and one or more additives.